Vor Biopharma announced positive clinical data from its Phase 1/2 study of trem-cel in combination with Mylotarg for relapsed/refractory acute myeloid leukemia (AML). The data demonstrated reliable engraftment, shielding from Mylotarg toxicity, and early evidence of patient benefit. Vor Bio plans to pursue a registrational trial for trem-cel + Mylotarg and is also exploring other potential applications for its platform.